Should I buy Xylem Inc. (XYL) stock or is it too late?
⭐ The most reliable of them, either direction: Jefferies — 80% of its targets hit on this sector (288 calls tested). It aims for $150 (+33 %), call made on August 25, 2026, maturing on August 25, 2027 (3 d ago).
Firm-by-firm track record on Xylem Inc.
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Barclays | 80 % | +15.9 % | 5 | $159 +41% |
| RBC Capital | 70 % | +14.7 % | 20 | $164 +46% |
| Stifel | 70 % | +9.1 % | 20 | $160 +42% |
| Baird | 57 % | +8.1 % | 7 | $165 +46% |
| Oppenheimer | 50 % | +8.0 % | 8 | $158 +40% |
| BMO Capital | 100 % | +15.0 % | 6 | — |
| Morgan Stanley | 40 % | +5.7 % | 5 | — |
| Credit Suisse | 54 % | -11.7 % | 13 | — |
✅ Reasons to believe
- 80% of analysts rate it a buy (Buy consensus, 10 ratings) — a sign of market conviction.
- Median price target $160, i.e. +42% from the current price ($113).
- The most reliable firm on XYL, Barclays (80% hit rate, 5 scored calls), targets $159 (call made on July 29, 2026, maturing on July 29, 2027) (+41%) in its most recent call, and $165 (call made on September 19, 2025, maturing on September 19, 2026) (+46%) in the one coming due soonest.
- 5 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 10 ratings, 2 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
The analyst consensus on XYL
Median target $160 (+42%) · 10 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Xylem Inc. now?
We won't decide for you. The facts: 80% of analysts rate it a buy, median target $160 (+42%), and Barclays (most reliable on XYL, 80%) targets $159. Weigh that against valuation (P/E ~27). This is not personalized advice.
Is it too late to invest in Xylem Inc.?
Not according to analysts: the median target ($160) is still +42% above the current price ($113) (most reliable on XYL: Barclays, 80%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Xylem Inc. still worth investing in?
It depends on the gap between the price ($113) and its estimated value: analysts target $160 on median (+42%), with 80% buys (most reliable on XYL: Barclays, 80%). Cross-check with their real reliability on XYL and the cautions above. Information, not advice.
What's the main risk in buying XYL?
The consensus is not unanimous: of 10 ratings, 2 are neutral.
→ Go deeper: the full Xylem Inc. profile (consensus, analyst reliability, price target, performance).